Literature DB >> 20354539

Radiotherapy: Neurocognitive considerations in the treatment of brain metastases.

Nicholas F Marko1, Robert J Weil.   

Abstract

The results of a randomized, controlled trial investigating the neurocognitive effects of stereotactic radiosurgery (SRS), with or without whole-brain radiation therapy (WBRT), to treat brain metastases demonstrated a significant reduction in learning and memory, associated with the addition of WBRT to SRS. the results indicate that SRS monotherapy is an effective and safe initial management strategy for brain metastases.

Entities:  

Mesh：

Year:  2010        PMID： 20354539     DOI： 10.1038/nrclinonc.2010.30

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

Review 3.  Adjuvant whole brain radiotherapy: strong emotions decide but rational studies are needed.

Authors:  Paul D Brown; Anthony L Asher; Elana Farace
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-30       Impact factor: 7.038

4.  A randomized trial of surgery in the treatment of single metastases to the brain.

Authors:  R A Patchell; P A Tibbs; J W Walsh; R J Dempsey; Y Maruyama; R J Kryscio; W R Markesbery; J S Macdonald; B Young
Journal:  N Engl J Med       Date:  1990-02-22       Impact factor: 91.245

5.  Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04.

Authors:  W F Regine; C Scott; K Murray; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

6.  Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications.

Authors:  William F Regine; Jennifer L Huhn; Roy A Patchell; William H St Clair; James Strottmann; Ali Meigooni; Michael Sanders; A Byron Young
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

7.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

Review 8.  Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.

Authors:  Christina A Meyers; Paul D Brown
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.

Authors:  Penny K Sneed; John H Suh; Steven J Goetsch; Seema N Sanghavi; Richard Chappell; John M Buatti; William F Regine; Eduardo Weltman; Vernon J King; John C Breneman; Paul W Sperduto; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-01       Impact factor: 7.038
  10 in total
  6 in total

1.  Prophylactic cranial irradiation: the state of the art and areas of uncertainty.

Authors:  S Vilar-González; J J Aristu-Mendioroz; A Pérez-Rozos
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  A new survival score for patients with brain metastases from non-small cell lung cancer.

Authors:  D Rades; L Dziggel; B Segedin; I Oblak; V Nagy; A Marita; S E Schild; N T Trang; M T Khoa
Journal:  Strahlenther Onkol       Date:  2013-06-07       Impact factor: 3.621

3.  A simple survival score for patients with brain metastases from breast cancer.

Authors:  D Rades; L Dziggel; B Segedin; I Oblak; V Nagy; A Marita; S E Schild; N T Trang; M T Khoa
Journal:  Strahlenther Onkol       Date:  2013-06-07       Impact factor: 3.621

4.  Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation.

Authors:  Sarah J E Wong-Goodrich; Madeline L Pfau; Catherine T Flores; Jennifer A Fraser; Christina L Williams; Lee W Jones
Journal:  Cancer Res       Date:  2010-09-30       Impact factor: 12.701

5.  A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-07-18       Impact factor: 3.621

Review 6.  Using lithium as a neuroprotective agent in patients with cancer.

Authors:  Mustafa Khasraw; David Ashley; Greg Wheeler; Michael Berk
Journal:  BMC Med       Date:  2012-11-02       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.